Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
The #ALS space—and the HEALEY ALS Platform Trial—saw two more failures this week, from Denali Therapeutics and AbbVie/Calico Life Sciences. After a disappointing 2024 for the space ...
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Zacks.com on MSN4d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ...
The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ALS ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Gov. Maura Healey filed a $2.5 billion borrowing bill Tuesday that would dump cash into Massachusetts’ public higher education system to update aging infrastructure that the first-term Democrat ...
(WJAR) — The Maura Healey administration announced a bill on Tuesday that aims to modernize public higher education in Massachusetts. She made the announcement in Bridgewater at the campus of ...
The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 in amyotrophic lateral sclerosis (ALS). The lift allows Amylyx to open US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback